Anti-AER61/EOGT Rabbit Monoclonal Antibody for WB and ELISA - Q5NDL2

Core Product Specifications and Parameters

Biological Background: EGF domain-specific O-linked N-acetylglucosamine transferase Function and Localization

• Encoded by the EOGT gene (also known as AER61, AOS4, or EOGT1), the protein is designated as EGF domain-specific O-linked N-acetylglucosamine transferase (EOGT), an enzyme that catalyzes O-GlcNAc modification on extracellular proteins.
• Catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in extracellular proteins, with specificity for the Thr residue located between the fifth and sixth conserved cysteines of folded EGF-like domains.
• Localizes to the endoplasmic reticulum lumen, where it adds O-GlcNAc to nascent glycoproteins during their processing.
• Alternative splicing produces multiple isoforms, and the protein belongs to the glycosyltransferase family, highlighting its role in post-translational modification.
• Associated with alternative splicing and disease variants, indicating potential roles in human pathology; identified in proteomics screens as a reference proteome member.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 1-150 of human AER61 (NP_775925.1), covering the N-terminal region; this may target the signal peptide or early domain.
• For WB, consider using reducing conditions and validate the band around 62 kDa in lysates from human, mouse, or rat tissues/cells.
• For ELISA, ensure proper coating of recombinant protein or relevant cell lysates to confirm specificity and sensitivity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-AER61/EOGT antibody is ideal for glycobiology and O-GlcNAc modification studies, offering a reliable tool for WB and ELISA. Beyond individual antibodies, CamelBio supplies validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and can source rare-target raw materials to accelerate your IVD assay development.